NO954390L - Method of combating acyclovir-resistant Herpes simplex virus infections - Google Patents

Method of combating acyclovir-resistant Herpes simplex virus infections

Info

Publication number
NO954390L
NO954390L NO954390A NO954390A NO954390L NO 954390 L NO954390 L NO 954390L NO 954390 A NO954390 A NO 954390A NO 954390 A NO954390 A NO 954390A NO 954390 L NO954390 L NO 954390L
Authority
NO
Norway
Prior art keywords
alkyl
amino acid
acyclovir
peptide derivative
combating
Prior art date
Application number
NO954390A
Other languages
Norwegian (no)
Other versions
NO954390D0 (en
Inventor
James Gus Chafouleas
Robert Deziel
Original Assignee
Bio Mega Boehringer Ingelheim
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bio Mega Boehringer Ingelheim filed Critical Bio Mega Boehringer Ingelheim
Publication of NO954390D0 publication Critical patent/NO954390D0/en
Publication of NO954390L publication Critical patent/NO954390L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Beskrevet heri er en fremgangsmåte for behandling av acyklovir-resistente herpes-infeksjoner hos pattedyr. Frem- gangsmåten omfatter administrering av et peptidderivat eller . en kombinasjon av peptidderivatet og en antivirusnukleosid- analog til det infiserte pattedyr. Peptidderivatet som anven- des for fremgangsmåten er representert vd formelen A-B-D- CH2CH{CH2C(O)R1}C(O)-NHCH{CR2(R3)COOH}C(0)-E/ hvori A er en terminal gruppe, f.eks. en eventuelt substituert fenyl- alkanoyl, og B er en N-metylaminosyrerest; eller A og B til sammen danner en mettet alkylaminokarbonyl; D er en aminosyre- rest; R1 er f.eks. en alkyl, cykloalkyl, eller en mono- substituert eller en disubstituert amino; R2 er f.eks. hydro- gen eller alkyl og R3 er alkyl, eller R2 er hydrogen og R3 er fenylalkyl, eller R2 og R3 er bundet sammen under dannelse av en cykloalkyl; og E er en terminalenhet, f.eks. en alkylamino eller et enverdig aminosyreradikal såsom NHCH(alkyl)C(0)OH.Described herein is a method of treating acyclovir-resistant herpes infections in mammals. The method comprises administering a peptide derivative or. a combination of the peptide derivative and an antivirus nucleoside analogue to the infected mammal. The peptide derivative used for the process is represented by the formula ABD-CH2CH {CH2C (O) R1} C (O) -NHCH {CR2 (R3) COOH} C (O) -E / wherein A is a terminal group, f. ex. an optionally substituted phenyl alkanoyl, and B is an N-methyl amino acid residue; or A and B together form a saturated alkylaminocarbonyl; D is an amino acid residue; R1 is e.g. an alkyl, cycloalkyl, or a mono-substituted or a disubstituted amino; R2 is e.g. hydrogen or alkyl and R 3 is alkyl or R 2 is hydrogen and R 3 is phenylalkyl or R 2 and R 3 are bonded together to form a cycloalkyl; and E is a terminal unit, e.g. an alkylamino or a monovalent amino acid radical such as NHCH (alkyl) C (O) OH.

NO954390A 1993-05-03 1995-11-02 Method of combating acyclovir-resistant Herpes simplex virus infections NO954390L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CA002095408A CA2095408A1 (en) 1993-05-03 1993-05-03 Method of combating acyclovir-resistant herpes simplex viral infections
PCT/CA1994/000242 WO1994025046A1 (en) 1993-05-03 1994-04-29 Method of combating acyclovir-resistant herpes simplex viral infections

Publications (2)

Publication Number Publication Date
NO954390D0 NO954390D0 (en) 1995-11-02
NO954390L true NO954390L (en) 1996-01-02

Family

ID=4151571

Family Applications (1)

Application Number Title Priority Date Filing Date
NO954390A NO954390L (en) 1993-05-03 1995-11-02 Method of combating acyclovir-resistant Herpes simplex virus infections

Country Status (13)

Country Link
EP (1) EP0767671A1 (en)
JP (1) JPH08509476A (en)
KR (1) KR960701651A (en)
CN (1) CN1126438A (en)
AU (1) AU683465B2 (en)
BR (1) BR9406575A (en)
CA (1) CA2095408A1 (en)
CZ (1) CZ287795A3 (en)
HU (1) HUT73779A (en)
NO (1) NO954390L (en)
SG (1) SG48806A1 (en)
SK (1) SK132695A3 (en)
WO (1) WO1994025046A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6599887B2 (en) 1988-07-07 2003-07-29 Chimerix, Inc. Methods of treating viral infections using antiviral liponucleotides
US5817638A (en) * 1988-07-07 1998-10-06 Nexstar Pharmaceuticals, Inc. Antiviral liponucleosides: treatment of hepatitis B
US6252060B1 (en) 1988-07-07 2001-06-26 Nexstar Pharmaceuticals, Inc. Antiviral liponucleosides: treatment of hepatitis B
CA2139169C (en) * 1994-12-28 2001-05-01 Boehringer Ingelheim (Canada) Ltd./ Boehringer Ingelheim (Canada) Ltee Antiherpes peptidomimetic compounds
CN109627243B (en) * 2019-01-09 2021-06-29 广西壮族自治区水产科学研究院 Penciclovir-copper complex, synthetic method and application thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2033448C (en) * 1990-12-31 1996-11-26 Boehringer Ingelheim (Canada) Ltd./ Boehringer Ingelheim (Canada) Ltee Antiherpes compositions and method of use
SG42995A1 (en) * 1992-03-12 1997-10-17 Bio Mega Boehringer Ingelheim Isosteric antiherpes peptide derivatives

Also Published As

Publication number Publication date
WO1994025046A1 (en) 1994-11-10
SK132695A3 (en) 1996-10-02
HU9503135D0 (en) 1996-01-29
AU6642394A (en) 1994-11-21
HUT73779A (en) 1996-09-30
CA2095408A1 (en) 1994-11-04
NO954390D0 (en) 1995-11-02
CN1126438A (en) 1996-07-10
BR9406575A (en) 1996-03-19
AU683465B2 (en) 1997-11-13
SG48806A1 (en) 1998-05-18
EP0767671A1 (en) 1997-04-16
JPH08509476A (en) 1996-10-08
KR960701651A (en) 1996-03-28
CZ287795A3 (en) 1996-06-12

Similar Documents

Publication Publication Date Title
NO960713D0 (en) Substituted azaindolylidene compounds and process for their preparation
NO954390L (en) Method of combating acyclovir-resistant Herpes simplex virus infections
ATE169931T1 (en) ISOSTERIC PEPTIDE DERIVATIVES AGAINST HERPES
DK0556119T3 (en) Pyrrolidine derivatives substituted at the three-position with a saturated or unsaturated fatty acid group, process for their preparation, and pharmaceutical preparations with thromboxane A2 inhibitory activity containing them
ES2152269T3 (en) INHIBITORS OF RIBONUCLEOTIDO-REDUCTASA DE HERPESVIRUS.
NO921908L (en) AMINOSYRAZETIDINYL SUBSTITUTED PYRIDON DERIVATIVES, THEIR PREPARATION AND USE AS MEDICINES
RU93004779A (en) DERIVATIVES OF PEPTIDES AND THEIR THERAPEUTICALLY ACCEPTABLE SALTS, METHOD FOR PRODUCING THEREOF, PHARMACEUTICAL AND COSMETIC COMPOSITION, METHOD FOR TREATING INFECTIOUS VIRUSES WITH HERPES VIRUS
FI944076A (en) Process for Preparation of N- (3-Hydroxy-4-piperidinyl) (dihydrobenzofuran, dihydro-2H-benzopyran or dihydrobenzodioxine) carboxamide derivatives and intermediates